Tocilizumab in COVID-19: Beware the risk of intestinal perforation

Int J Antimicrob Agents. 2020 Jul;56(1):106009. doi: 10.1016/j.ijantimicag.2020.106009. Epub 2020 May 7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Betacoronavirus*
  • COVID-19
  • Coronavirus Infections / drug therapy*
  • Humans
  • Intestinal Perforation / chemically induced*
  • Pandemics
  • Peptidyl-Dipeptidase A / physiology
  • Pneumonia, Viral / drug therapy*
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2
  • tocilizumab